Madrigal Pharmaceuticals, Inc. (MDGL) Q2 FY25 Earnings Call

Q2 FY25 results, source: company transcript and SEC filings
QuarterQ2 FY25
Call date2025-08-05
Length53 minutes
EPS$-1.90
EPS consensus$-3.48
Revenue$212.8M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All MDGL earnings ยท Back to MDGL overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.